Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS

(ALXN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/16/2019 07/17/2019 07/18/2019 07/19/2019 07/22/2019 Date
122.82(c) 123.41(c) 123.26(c) 120.8(c) 122.32 Last
1 532 898 1 706 526 1 114 031 1 521 159 1 680 952 Volume
-0.18% +0.48% -0.12% -2.00% +1.26% Change
More quotes
Financials (USD)
Sales 2019 4 781 M
EBIT 2019 2 627 M
Net income 2019 1 768 M
Finance 2019 377 M
Yield 2019 -
Sales 2020 5 438 M
EBIT 2020 2 937 M
Net income 2020 1 985 M
Finance 2020 1 894 M
Yield 2020 -
P/E ratio 2019 15,7x
P/E ratio 2020 14,0x
EV / Sales2019 5,66x
EV / Sales2020 4,70x
Capitalization 27 429 M
More Financials
Company
Alexion Pharmaceuticals specializes in the research and development of therapeutic products used in treating hematological and cardiovascular diseases, auto-immune diseases, and cancers. At the end of 2017, the group had a portfolio of 5 products in clinical development. Net sales are distributed... 
Sector
Pharmaceuticals
Calendar
07/24Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS
07/10ALEXION PHARMACEUTICALS : to Report Second Quarter 2019 Results On Wednesday, Ju..
BU
07/03ALEXION PHARMACEUTICALS : ULTOMIRIS® (ravulizumab) Receives Marketing Authorizat..
BU
06/29ALEXION PHARMACEUTICALS : and Minoryx Therapeutics to Present at SMi's Orphan Dr..
AQ
06/28Sarepta surges after Pfizer gene therapy data raises safety concerns
RE
06/27ALEXION PHARMACEUTICALS : Says FDA Approves Soliris for Neuromyelitis Optica Spe..
DJ
06/27ALEXION PHARMACEUTICALS : ADDING MULTIMEDIA Alexion Receives FDA Approval of SOL..
BU
06/21ALEXION PHARMACEUTICALS : U.S. FDA Accepts Supplemental Biologics License Applic..
AQ
06/20ALEXION PHARMACEUTICALS : Gets FDA Priority Review of Ultomiris in Kidney Disord..
DJ
06/20ALEXION PHARMACEUTICALS : U.S. FDA Accepts Supplemental Biologics License Applic..
BU
06/19ALEXION PHARMACEUTICALS : ULTOMIRIS Receives Marketing Authorization from Japan'..
AQ
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS
More recommendations
Sector news : Biopharmaceuticals
12:38pGLAXOSMITHKLINE : ViiV Healthcare Finds Positive Data In HIV Drug Study
DJ
12:04pBAYER : Iberogast Drug Is Safe
DJ
11:22aFDA Approves Multiple Applications for Generic Version of Lyrica
DJ
10:43aALLERGAN : Form 8.3 -
DJ
10:18aMERCK AND : Bayer sells Dr. Scholl's footcare brand to Yellow Wood Partners
RE
More sector news : Biopharmaceuticals
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 160,74  $
Last Close Price 122,32  $
Spread / Highest target 50,4%
Spread / Average Target 31,4%
Spread / Lowest Target 3,01%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP, Head-Research & Development
Andreas Rummelt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS24.08%27 088
CSL LIMITED21.40%71 775
BIOGEN-23.15%44 842
GRIFOLS24.80%19 360
SAMSUNG BIOLOGICS CO LTD--.--%16 204
BIOMARIN PHARMACEUTICAL INC.-4.20%14 607